Author: ALLISON GATLIN
Source
AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.
The post AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment appeared first on Investor’s Business Daily.